The announcement was made after market hours on Thursday, 6 June 2013.
Meanwhile, the S&P BSE Sensex was down 39.82 points or 0.2% at 19,479.67.
On BSE, 29,000 shares were traded in the counter as against average daily volume of 78,792 shares in the past one quarter.
The stock hit a high of Rs 163.45 and a low of Rs 157 so far during the day. The stock had hit a record high of Rs 292.20 on 5 December 2012. The stock had hit a 52-week low of Rs 150 on 16 May 2013.
The stock had underperformed the market over the past one month till 6 June 2013, sliding 13.68% compared with the Sensex's 0.78% fall. The scrip had also underperformed the market in past one quarter, declining 17.09% as against Sensex's 1.39% rise.
The small-cap company has equity capital of Rs 63.82 crore. Face value per share is Rs 10.
Claris Lifesciences said that the anti-infective drug is administered on adults suffering from infections such as pneumonia, acute bacterial sinusitis or complicated urinary tract injections etc. The intravenous route of administration is considered advantageous to the patient, Claris Lifesciences said.
Claris Lifesciences said it is also one of the few injectables companies in India to have its own front end in the US. The company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company now has 11 abbreviated new drug applications (ANDA) approved by the United States Food & Drug Administration. The company has total filing of 32 ANDAs.
Claris Lifesciences' consolidated net profit declined 28.6% to Rs 15.49 crore on 1% growth in net sales to Rs 182.15 crore in Q1 March 2013 over Q1 March 2012.
Claris Lifesciences is a sterile injectables pharmaceutical company with a market presence in 98 countries worldwide. The company manufactures and markets products across various therapeutic segments. A significant majority of these products are generic drugs that are capable of being directly injected into the human body and are predominantly used in the treatment of critical illnesses.
Powered by Capital Market - Live News
